ArticleContemporary clinical trials communications2025

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.